The Death of the Puffery Defense: How Back-to-Back Appellate Rulings Just Blew Up the Retail Labeling Playbook

For the better part of a decade, corporate defense counsel facing consumer labeling class actions have relied on a predictable, reliable playbook to choke out litigation in its infancy: file a motion to dismiss under Federal Rule of Civil Procedure 12(b)(6), argue that the label’s claims are either preempted by federal law or constitute non-actionable "puffery," and watch the district court toss the case before discovery even begins.

Those days are officially over.

In a span of just 48 hours in late July 2026, two separate federal appellate courts handed down decisions that fundamentally alter the landscape for consumer class actions. First, on July 29, the Tenth U.S. Circuit Court of Appeals ruled that British American Tobacco (BAT) must face class-action litigation over its "Natural American Spirit" cigarette labels. The very next day, a separate federal appeals court revived nationwide class-action claims against major drugmakers and retailers over "maximum strength" decongestant labeling.

Taken together, these rulings signal a profound judicial hostility toward early exit ramps in false advertising and consumer fraud litigation. For practicing defense attorneys, the message is clear: the appellate bench is no longer willing to play gatekeeper on what a "reasonable consumer" might believe. You are going to have to litigate these cases on the merits.

Breathing Life into the "Natural" Tobacco Claims

The Tenth Circuit’s revival of the British American Tobacco litigation is a masterclass in how federal courts are narrowing the scope of express preemption and tightening the definition of puffery. For years, plaintiffs have targeted BAT’s "Natural American Spirit" branding, arguing that words like "natural" and "additive-free" deceptively imply a safer cigarette.

The traditional defense relies heavily on the Federal Cigarette Labeling and Advertising Act (FCLAA), 15 U.S.C. § 1331 et seq., which expressly preempts state law requirements or prohibitions based on smoking and health with respect to the advertising or promotion of cigarettes. In the wake of the Supreme Court’s ruling in Altria Group, Inc. v. Good, 555 U.S. 70 (2008), the line between a preempted failure-to-warn claim and a surviving affirmative fraud claim has been fiercely contested.

By holding that BAT must face these class claims, the Tenth Circuit is effectively ruling that "natural" is not just an ethereal marketing buzzword—it is a factual, material representation that a jury must evaluate. The court rejected the premise that the FCLAA provides a blanket shield against state consumer protection laws when a manufacturer voluntarily makes affirmative, potentially misleading statements about the composition of its product.

"When a federal circuit court decides that a word as ambiguous as 'natural' requires factual development rather than judicial dismissal, it strips defendants of their most cost-effective weapon. The cost of defending a class action just multiplied exponentially."

"Maximum Strength" Faces Maximum Scrutiny

If the Tenth Circuit’s ruling was a left hook, the July 30 appellate decision reviving the "maximum strength" decongestant litigation was the knockout blow to the Rule 12(b)(6) strategy.

In the decongestant litigation, plaintiffs alleged that drugmakers and retailers deceived consumers by labeling products as "maximum strength" when, in fact, they provided no greater efficacy than standard doses, or were otherwise mischaracterized. The defense playbook here traditionally leans on the Food, Drug, and Cosmetic Act (FDCA) and the FDA’s over-the-counter (OTC) monograph system. Defendants routinely argue that if a label complies with an FDA monograph, state-law fraud claims are preempted under 21 U.S.C. § 379r. Alternatively, they argue that "maximum strength" is classic puffery—a subjective boast that no reasonable consumer would interpret as a binding clinical guarantee.

By reviving parts of this nationwide litigation, the appellate court rejected the notion that FDA compliance is an absolute shield against deceptive marketing claims, particularly when the phrase "maximum strength" implies an objective, measurable superiority that the product allegedly fails to deliver. The ruling aligns with a growing judicial consensus that if a marketing phrase can be measured or tested, it is not puffery; it is an actionable claim.

The Ripple Effect: Emboldened Plaintiffs and the Rule 23 Pivot

Why do these two appellate decisions matter so much for the trenches of civil litigation? Because in class-action practice, leverage is everything.

When a defendant loses a motion to dismiss in a nationwide consumer class action, the settlement value of the case skyrockets. The defendant is suddenly staring down the barrel of massive asymmetric e-discovery costs and the terrifying prospect of a class certification battle under Federal Rule of Civil Procedure 23. This appellate trend is already emboldening state enforcement and plaintiffs' counsel at the trial level—evidenced by Arizona’s aggressive September 11, 2026 filing accusing L’Oréal of concealing cancer risks tied to hair relaxers.

For defense counsel, the strategy must urgently pivot. If federal circuits are going to punt the "reasonable consumer" question to the jury, you can no longer rely on Rule 12(b)(6) to save your client. Instead, the battleground must shift entirely to defeating class certification under Rule 23(b)(3).

Here is the new tactical reality:

• Attack Typicality and Reliance: If the court says "natural" or "maximum strength" might mislead a consumer, you must prove at the certification stage that it didn't mislead every consumer. Dig into the individualized reasons consumers purchased the product to defeat Rule 23(b)(3) predominance.
• Weaponize Ascertainability: In low-dollar retail class actions (like cigarettes or OTC decongestants), consumers rarely keep receipts. Force plaintiffs to prove how they intend to identify class members without relying on self-serving affidavits.
• Front-Load Expert Testimony: You can no longer wait for summary judgment to deploy your consumer behavior experts. You need survey experts at the class certification stage to prove that the proposed class lacks a uniform interpretation of the challenged label.

The Tenth Circuit and its sister courts have spoken: the judiciary is getting out of the business of dismissing labeling claims on the pleadings. Corporate America’s legal departments need to brace for impact, budget for discovery, and prepare to fight these battles at the class certification stage. The era of the cheap, early exit is dead.